These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34435168)

  • 81. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
    Barthélémy P; Rioux-Leclercq N; Thibault C; Saldana C; Borchiellini D; Chevreau C; Desmoulins I; Gobert A; Hilgers W; Khalil A; Lemoine N; Schlürmann-Constans F; Négrier S
    Cancer Treat Rev; 2021 Jun; 97():102191. PubMed ID: 34015728
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
    Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
    Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
    Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
    Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
    John A; Spain L; Hamid AA
    Curr Oncol; 2023 Jan; 30(1):923-937. PubMed ID: 36661719
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
    Voss MH; Molina AM; Chen YB; Woo KM; Chaim JL; Coskey DT; Redzematovic A; Wang P; Lee W; Selcuklu SD; Lee CH; Berger MF; Tickoo SK; Reuter VE; Patil S; Hsieh JJ; Motzer RJ; Feldman DR
    J Clin Oncol; 2016 Nov; 34(32):3846-3853. PubMed ID: 27601542
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
    Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
    JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience.
    Al-Ezzi E; Mittal A; Veitch ZW; Zahralliyali A; Mejia NMD; Abdeljalil O; Alqaisi H; Kumar V; Hansen AR; Fallah-Rad N; Sridhar SS
    J Kidney Cancer VHL; 2024; 11(1):41-48. PubMed ID: 38450000
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.
    Borregales LD; Adibi M; Thomas AZ; Wood CG; Karam JA
    Ther Adv Urol; 2016 Apr; 8(2):130-41. PubMed ID: 27034725
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Immunologics and chemotherapeutics for renal cell carcinoma.
    Diamond E; Riches J; Faltas B; Tagawa ST; Nanus DM
    Semin Intervent Radiol; 2014 Mar; 31(1):91-7. PubMed ID: 24596445
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report.
    Zhang H; Cong X; Chen C; Liu Z
    Front Oncol; 2024; 14():1325999. PubMed ID: 38371628
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma.
    McKay RR; Bossé D; Choueiri TK
    J Clin Oncol; 2018 Oct; ():JCO2018790253. PubMed ID: 30372392
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Kidney Cancer Updates from the 2023 American Society of Clinical Oncology Annual Meeting in Chicago.
    Elias R; Ged Y; Singla N
    Kidney Cancer J; 2023 Jun; 21(2):58-63. PubMed ID: 38298522
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
    Soares A; Monteiro FSM; da Trindade KM; Silva AGE; Cardoso APG; Sasse AD; Fay AP; Carneiro APCD; Alencar Junior AM; de Andrade Mota AC; Santucci B; da Motta Girardi D; Herchenhorn D; Araújo DV; Jardim DL; Bastos DA; Rosa DR; Schutz FA; Kater FR; da Silva Marinho F; Maluf FC; de Oliveira FNG; Vidigal F; Morbeck IAP; Rinck Júnior JA; Costa LAGA; Maia MCDF; Zereu M; Freitas MRP; Dias MSF; Tariki MS; Muniz P; Beato PMM; Lages PSM; Velho PI; de Carvalho RS; Mariano RC; de Araújo Cavallero SR; Oliveira TM; Souza VC; Smaletz O; de Cássio Zequi S
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):183. PubMed ID: 38594593
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies.
    de Joode K; van de Geer WS; van Leenders GJLH; Hamberg P; Westgeest HM; Beeker A; Oosting SF; van Rooijen JM; Beerepoot LV; Labots M; Mathijssen RHJ; Lolkema MP; Cuppen E; Sleijfer S; van de Werken HJG; van der Veldt AAM
    Sci Rep; 2023 Jul; 13(1):10720. PubMed ID: 37400554
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Insulin receptor expression to predict resistance to axitinib and elucidation of the underlying molecular mechanism in metastatic renal cell carcinoma.
    Takahashi M; Daizumoto K; Fukawa T; Fukuhara Y; Bando Y; Kowada M; Dondoo TO; Sasaki Y; Tomida R; Ueno Y; Tsuda M; Kusuhara Y; Yamaguchi K; Yamamoto Y; Uehara H; Kanayama H
    Br J Cancer; 2023 Aug; 129(3):521-530. PubMed ID: 37355721
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma.
    Osterman CK; Rose TL
    Kidney Cancer; 2020; 4(1):15-27. PubMed ID: 34435168
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
    Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
    Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
    Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
    Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.